Tarsus Pharmaceuticals Inc
$ 64.79
-0.83%
07 Aug - close price
- Market Cap 2,866,876,000 USD
- Current Price $ 64.79
- High / Low $ 68.00 / 63.75
- Stock P/E N/A
- Book Value 8.11
- EPS -1.11
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.06 %
- ROE -0.14 %
- 52 Week High 85.25
- 52 Week Low 47.60
About
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new therapeutic candidates for ophthalmic conditions. The company is headquartered in Irvine, California.
Analyst Target Price
$93.50
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-06 | 2026-05-06 | 2026-02-23 | 2025-11-04 | 2025-08-06 | 2025-05-01 | 2025-02-25 | 2024-11-13 | 2024-08-08 | 2024-05-08 | 2024-02-27 | 2023-11-09 |
| Reported EPS | -0.43 | -0.16 | -0.2 | -0.3 | -0.48 | -0.64 | -0.6 | -0.61 | -0.83 | -0.99 | -1.31 | -1.27 |
| Estimated EPS | -0.21 | -0.42 | -0.0836 | -0.33 | -0.36 | -0.63 | -0.8157 | -1 | -0.8 | -1.25 | -1.36 | -1.27 |
| Surprise | -0.22 | 0.26 | -0.1164 | 0.03 | -0.12 | -0.01 | 0.2157 | 0.39 | -0.03 | 0.26 | 0.05 | 0 |
| Surprise Percentage | -104.7619% | 61.9048% | -139.2344% | 9.0909% | -33.3333% | -1.5873% | 26.4435% | 39% | -3.75% | 20.8% | 3.6765% | 0% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TARS
2026-08-06 21:41:28
Latham & Watkins LLP advised Alkeus Pharmaceuticals on its acquisition by Tarsus Pharmaceuticals, Inc. The deal, announced on July 31, 2026, involves Tarsus acquiring Alkeus, a privately held retinal disease-focused biotechnology company developing gildeuretinol (ALK-001) for Stargardt disease. A comprehensive legal team from Latham & Watkins, led by partners Scott Shean, Andrew Clark, and Shannon Cheng, provided counsel across various specializations for the transaction.
2026-08-06 19:40:26
Tarsus Pharmaceuticals plans to acquire Alkeus Pharmaceuticals, including its late-stage investigational therapy for Stargardt disease, gildeuretinol acetate (ALK-001). The deal involves an estimated $450 million upfront consideration in cash and stock, plus potential future milestones and royalties. ALK-001 has received multiple FDA designations and shown promising results in clinical trials for slowing retinal lesion growth in Stargardt disease.
2026-08-06 17:40:26
Tarsus Pharmaceuticals, Inc.'s average 12-month stock price target has been lowered slightly from $94.22 to $93.57 by 7 analysts, with individual forecasts ranging from $84 to $104 per share. Based on the August 5th closing price, this updated target suggests a potential upside of approximately 53%. The consensus rating from all 7 analysts remains a "Buy."
2026-08-06 14:20:26
Tarsus Pharmaceuticals (TARS) reported a Q2 loss of $0.43 per share, exceeding the Zacks Consensus Estimate of a $0.21 loss, but surpassed revenue expectations with $173.91 million. Despite consistently beating revenue estimates, the stock has underperformed the S&P 500 year-to-date, and its current Zacks Rank #4 (Sell) suggests potential future underperformance. The company's earnings outlook and industry trends will be key factors for investors moving forward.
2026-08-06 13:40:27
Tarsus Pharmaceuticals announced its plan to acquire Alkeus Pharmaceuticals in a deal valued at up to $800 million. This acquisition will expand Tarsus's eye disease pipeline by adding an experimental oral therapy for a rare inherited retinal disorder for which there is currently no approved U.S. treatment. The deal is structured as a cash-and-stock transaction.
2026-08-06 10:40:27
Tarsus Pharmaceuticals announced an oversubscribed private placement (PIPE) expected to generate approximately $125.0 million in gross proceeds. The company will sell 2,098,519 shares of common stock at $56.00 per share and pre-funded warrants for 133,625 shares. The financing includes participation from both existing and new institutional investors, with closing anticipated on August 7, 2026.
